Loading...
GLP-3 RT
Add to Wishlist
Triple Receptor Agonist — Advanced Metabolic Research Compound
In Stock
Select Size
$100.00$120.00
You Save
$20.00In Stock — Ships Same Day
Includes
5mg research compound
Third-party lab tested
Free shipping on orders over $150
30-day money-back guarantee
Overview
Retatrutide (LY3437943) is a first-in-class triple incretin receptor agonist that simultaneously engages GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors through a single 39-amino acid peptide chain with a C20 fatty diacid modification for albumin binding and extended pharmacokinetics. This triple mechanism is unique in metabolic peptide research: GLP-1 receptor activation suppresses appetite and stimulates glucose-dependent insulin secretion; GIP receptor engagement potentiates insulin response and may improve beta-cell function; and glucagon receptor activation increases hepatic fatty acid oxidation, energy expenditure, and thermogenesis. Phase 2 clinical data published in the New England Journal of Medicine reported unprecedented body weight reductions of up to 24.2% at 48 weeks with the highest dose, exceeding results observed with both semaglutide (GLP-1 only) and tirzepatide (dual GIP/GLP-1). The glucagon receptor component provides the mechanistic addition absent from dual agonists, driving increased energy expenditure rather than relying solely on caloric intake reduction. Retatrutide is currently in Phase 3 clinical trials for metabolic indications. This is a research-grade compound for laboratory investigation, not an FDA-approved product.
Handling & Storage
Published research protocols reference weekly subcutaneous administration. Store refrigerated at 2-8°C.
Published Research Protocols
Published research protocols reference gradual titration with incremental increases every 4 weeks. Consult applicable literature for specific research applications.
Research Applications
Triple Receptor Activation
Simultaneously engages GLP-1, GIP, and glucagon receptors in a single molecule — the only triple agonist in advanced clinical development. Phase 2 data demonstrated that this three-receptor approach produced body weight reductions of up to 24.2% at 48 weeks, surpassing results achieved by single and dual agonists in comparable timeframes.
Initial effects within first month
Research Studies
Enhanced Energy Expenditure
Glucagon receptor activation increases basal metabolic rate through hepatic fatty acid oxidation and thermogenesis, directly increasing caloric expenditure rather than relying solely on appetite suppression. This energy expenditure component is the mechanistic advantage that distinguishes retatrutide from dual GIP/GLP-1 agonists like tirzepatide.
Initial effects within first month
Research Studies
Appetite Regulation
Engages both GLP-1 and GIP receptor-mediated satiety pathways simultaneously, providing redundant appetite suppression through multiple hypothalamic and brainstem signaling cascades. Clinical research subjects reported significant reductions in hunger scores and caloric intake, consistent with the combined incretin receptor activation profile.
Initial effects within first month
Research Studies
Frequently Asked Questions
What makes Retatrutide a triple agonist versus dual agonists?
Retatrutide activates three receptors — GLP-1, GIP, and glucagon — in a single molecule, while tirzepatide activates only GIP and GLP-1, and semaglutide activates only GLP-1. The addition of glucagon receptor agonism introduces energy expenditure and hepatic fat oxidation mechanisms that are absent from dual agonists, which is believed to explain the superior weight reduction observed in Phase 2 clinical data (up to 24.2% at 48 weeks).
What is the current clinical development status of Retatrutide?
Retatrutide (LY3437943) completed Phase 2 clinical trials with results published in the New England Journal of Medicine in 2023, and Phase 3 trials are ongoing. It is being developed by Eli Lilly. This PEPCELL product is a research-grade compound and is not the investigational drug used in those trials.
How should Retatrutide be reconstituted?
Reconstitute lyophilized retatrutide with bacteriostatic water, injecting slowly along the vial wall to avoid disrupting the peptide structure. The C20 fatty diacid acylation provides good solution stability. Do not shake. After reconstitution, store at 2-8°C and use within 30 days.
What purity verification does PEPCELL perform on Retatrutide?
Each retatrutide batch undergoes independent third-party analysis at Janoshik Analytical Laboratory, including HPLC purity testing and mass spectrometry identity confirmation. Current batches test at 99.2% purity with batch-specific Certificates of Analysis available for every lot.
Is Retatrutide intended for human use?
Retatrutide is sold exclusively for in-vitro research and laboratory investigation. It is not an FDA-approved drug — retatrutide remains in Phase 3 clinical trials and has not been approved for any therapeutic use. This research-grade compound is not intended for human consumption or self-administration.
Important Notice
Not for human consumption. This product is sold exclusively for in-vitro research and laboratory use. It is not a drug, supplement, food item, or cosmetic and has not been evaluated by the FDA.
The research data and clinical references cited on this page are provided for educational reference only and do not constitute medical advice. This product must be handled by qualified research professionals in accordance with all applicable institutional and regulatory guidelines.
Use is restricted to qualified researchers or laboratories operating within appropriate legal and ethical research guidelines. By purchasing, you confirm you are acquiring this product solely for lawful research purposes.
Research Articles
Published research and educational content related to GLP-3 RT
Research13 min read
Metabolic Research Peptides: Semaglutide vs Tirzepatide vs Retatrutide
A comparative analysis of single, dual, and triple incretin receptor agonists in metabolic research, examining mechanism differences, published clinical data, and structural innovations driving this rapidly evolving field.
Dr. James ParkResearch Analyst
Research12 min read
Semaglutide: A Comprehensive Research Guide to GLP-1 Receptor Agonists
An in-depth exploration of semaglutide research, covering its development history, GLP-1 receptor mechanism, pharmacokinetics, and how it compares to other incretin-based peptides in published studies.
Dr. James ParkResearch Analyst
